Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal Osteoporosis
- 3 May 1990
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 322 (18) , 1265-1271
- https://doi.org/10.1056/nejm199005033221803
Abstract
Progressive bone loss in osteoporosis results from bone resorption in excess of bone formation. We conducted a double-blind study in 66 women with postmenopausal osteoporosis of therapy with etidronate, a diphosphonate compound that reduces bone resorption by inhibiting osteoclastic activity.This publication has 24 references indexed in Scilit:
- Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1–38)hPTH and diphosphonate EHDPJournal of Molecular Medicine, 1988
- Long-Term Follow-up Observations on Treatment in Paget??s Disease of BonePublished by Wolters Kluwer Health ,1987
- Experimental Basis for the Use of Bisphosphonates in Paget??s Disease of BoneClinical Orthopaedics and Related Research, 1987
- Assessment of Metabolic Bone Diseases by Quantitative Computed TomographyPublished by Wolters Kluwer Health ,1985
- TREATMENT OF OSTEOPOROTIC FRACTUREThe Lancet, 1984
- Reconstruction of the resorptive site in iliac trabecular bone: A kinetic model for bone resorption in 20 normal individualsMetabolic Bone Disease and Related Research, 1984
- Diphosphonates: History and mechanisms of actionMetabolic Bone Disease and Related Research, 1981
- Measurement of bone mineral content (BMC) of the lumbar spine, I. Theory and application of a new two-dimensional dual-photon attenuation methodScandinavian Journal of Clinical and Laboratory Investigation, 1980
- Diphosphonate Treatment of Paget's Disease of BoneHormone and Metabolic Research, 1974
- Tetracycline-based histological analysis of bone remodelingCalcified Tissue International, 1969